Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02911701
Other study ID # 16-147
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 2016
Est. completion date January 10, 2018

Study information

Verified date July 2023
Source University of New Mexico
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

NSAIDs, specifically cyclo-oxygenase (COX) inhibitors, are known to increase blood pressure over time in non-pregnant adults, but the effect of COX-inhibitors on blood pressure in the setting of preeclampsia have not been well studied. This study aims to assess the effect of avoiding COX-inhibitors on postpartum blood pressure control among women diagnosed with preeclampsia with severe features. Eligible women will be randomized to receive either acetaminophen or ibuprofen for postpartum pain control. Both agents are first line therapies for pain control although ibuprofen has better pain control than acetaminophen. The primary outcome will be duration of postpartum severe-range hypertension.


Description:

The proposed study is a randomized, controlled, double-masked trial comparing the effect of postpartum acetaminophen and ibuprofen on blood pressure among women with preeclampsia. Study participants will be randomized to receive either acetaminophen or ibuprofen for mild postpartum pain control. Study participants, study personnel and providers will be blinded to randomization status of study participants. Potential study participants will be enrolled when they are diagnosed with a severe hypertensive disorder of pregnancy. This will usually occur prior to delivery, but may occur up to 6 hours after delivery. Patients diagnosed with preeclampsia without severe features will also be approached and enrolled at the time of diagnosis in anticipation for possible progression to preeclampsia with severe features. Once enrolled, study participants will not be randomized until delivery, at which time they will be randomized to receive either acetaminophen or ibuprofen for mild postpartum pain. Both groups will have available oxycodone for moderate to severe pain, per our routine. Study group allocation will only be known by the investigational pharmacy. The ibuprofen and acetaminophen will be made to appear identical to each other and will be unmarked through encapsulation. Block randomization will be used to ensure equal allocation to the two study arms. For the duration of study participation, study participants will undergo postpartum monitoring with vital sign measurements (including blood pressure) every 4 hours, pain assessment with each administration of study medication, as well as daily evaluation of laboratory studies until they have normalized to the satisfaction of their provider. Study participants will receive the study drug every 6 hours from the time of delivery until hospital discharge, unless they refuse. Study participation will be complete upon hospital discharge. Study participants will be contacted by a study team member 6 weeks after delivery to ask about any additional complications or symptoms requiring visits to the emergency department or hospital readmission. Descriptive factors and clinical outcomes will be extracted from the medical record and de-identified by study personnel during each day of study participation.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date January 10, 2018
Est. primary completion date November 7, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - ability to give informed consent - diagnosis of a "severe" hypertensive disorder of pregnancy: - preeclampsia with severe features - chronic hypertension with superimposed preeclampsia with severe features - HELLP syndrome: hemolysis, elevated liver function tests, low platelets - eclampsia - not yet delivered or less than 6 hours after delivery Exclusion Criteria: - current incarceration - serum creatinine > 1.0 mg/dL or suspicion of acute kidney injury - AST (aspartate aminotransferase) >200 unit/L - ALT (alanine aminotransferase) > 200 unit/L - known allergy or sensitivity to NSAIDs or acetaminophen - delivery > 6 hours prior to enrollment - chronic kidney disease - chronic liver disease - prior liver transplant - chronic infectious hepatitis - gastritis - gastro-esophageal reflux disease (GERD) - peptic ulcer disease - bleeding disorder - provider feels that participation is not in the best interest of the patient

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Acetaminophen

Ibuprofen


Locations

Country Name City State
United States University of New Mexico Health Sciences Center Albuquerque New Mexico

Sponsors (1)

Lead Sponsor Collaborator
University of New Mexico

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Duration of Severe-range Hypertension After Delivery length of time from delivery to the last severe range blood pressure (160/110mm Hg) measured duration of postpartum hospitalization (approximately 3-7 days)
Secondary Length of Hospitalization number of days from delivery until hospital discharge duration of postpartum hospitalization (approximately 3-7 days)
Secondary Mean Arterial Pressure Over the Entire Postpartum Hospitalization computed mean arterial pressure using all measured blood pressures during postpartum hospitalization duration of postpartum hospitalization (approximately 3-7 days)
Secondary Mean Arterial Pressure, Stratified by Postpartum Day 1, 2, 3, Etc. computed mean arterial pressure using all measured blood pressures during postpartum hospitalization, stratified by postpartum day (1, 2, 3, etc.) duration of postpartum hospitalization (approximately 3-7 days)
Secondary Mean Total Number of Severe Range Blood Pressure Measurements in Each Study Arm. mean total number of severe range blood pressure (defined as SBP >160mmGh or DBP >110mmHg) measurements in each study arm duration of postpartum hospitalization (approximately 3-7 days)
Secondary Proportion of Study Participants in Each Study Arm Who Have Any Postpartum Severe Range BPs Severe-range hypertension (defined as SBP > 160 mmHg or DBP >1100 mmHg) during postpartum stay duration of postpartum hospitalization (approximately 3-7 days)
Secondary Mean Maximum Measured Blood Pressure for Entire Postpartum Hospitalization (in mm Hg) duration of postpartum hospitalization (approximately 3-7 days)
Secondary Proportion of Study Participants Requiring the Use of Scheduled Oral Antihypertensives at Discharge duration of postpartum hospitalization (approximately 3-7 days)
Secondary Number of Scheduled Oral Antihypertensive Agents Required at Discharge duration of postpartum hospitalization (approximately 3-7 days)
Secondary Need for Antihypertensives (Either Oral or Intravenous) for Acute Lowering of Blood Pressure Proportion in each arm who required one or more doses of antihypertensive medication given for acute lowering of BP duration of postpartum hospitalization (approximately 3-7 days)
Secondary The Proportion of Study Participants Requiring the Use of Intravenous Antihypertensives The proportion of study participants in each study arm who require any IV antihypertensives to acutely lower blood pressure during their postpartum hospital stay. duration of postpartum hospitalization (approximately 3-7 days)
Secondary Mean Daily Pain Level, as Reported by Patient on Scale From 1-10, Stratified by Postpartum Day Mean daily pain level, as reported by patient on scale from 1-10 (10 is most severe). duration of postpartum hospitalization (approximately 3-7 days)
Secondary Use of Opioid Analgesics, Measured in Morphine Milligram Equivalents Per Day, Stratified by Postpartum Day duration of postpartum hospitalization (approximately 3-7 days)
Secondary Serum Creatinine Trend From Day of Delivery to Day of Discharge duration of postpartum hospitalization (approximately 3-7 days)
Secondary Mean Drop in Hematocrit From Pre-delivery to the Nadir Prior to Discharge Mean difference in hematocrit from pre-delivery to postpartum nadir prior to discharge duration of postpartum hospitalization (approximately 3-7 days)
Secondary Composite of Adverse Events Adverse events include seizure, stroke, posterior reversible encephalopathy syndrome, repeat course of IV magnesium sulfate for seizure prophylaxis. duration of postpartum hospitalization (approximately 3-7 days)
Secondary Proportion of Study Participants in Each Study Arm With New Onset Postpartum Elevation of Liver Function Tests (AST, ALT) Above Twice the Normal Limit AST: Aspartate aminotransferase; ALT: alanine aminotransferase duration of postpartum hospitalization (approximately 3-7 days)
Secondary Proportion of Study Participants in Each Study Arm With New Onset Postpartum Acute Kidney Injury Acute kidney injury is defined as serum creatinine > 1.1mg/dL or double the baseline value duration of postpartum hospitalization (approximately 3-7 days)
Secondary Proportion of Study Participants in Each Study Arm With Delayed Postpartum Hemorrhage Delayed postpartum hemorrhage is defined as > 1000 mL of blood loss occuring > 24 hours after delivery duration of postpartum hospitalization (approximately 3-7 days)
See also
  Status Clinical Trial Phase
Recruiting NCT03299777 - Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan N/A
Completed NCT03650790 - C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies N/A
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Not yet recruiting NCT03302260 - Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial N/A
Completed NCT01911494 - Community Level Interventions for Pre-eclampsia N/A
Terminated NCT02025426 - Phenylephrine Versus Ephedrine in Pre-eclampsia Phase 4
Completed NCT01352234 - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Phase 4
Active, not recruiting NCT02031393 - Establishing First Trimester Markers for the Identification of High Risk Twin N/A
Terminated NCT00141310 - Sildenafil Citrate for the Treatment of Established Pre-Eclampsia Phase 2
Completed NCT00157521 - L-Arginine in Pre-Eclampsia Phase 3
Completed NCT04795154 - Prenatal Yoga as Complementary Therapy of Preeclampsia N/A
Completed NCT00004399 - Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia N/A
Completed NCT00005207 - Renin and Prorenin in Pregnancy N/A
Recruiting NCT04551807 - Natural Versus Programmed Frozen Embryo Transfer (NatPro) Phase 3
Terminated NCT04092829 - Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer N/A
Recruiting NCT06067906 - Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients N/A
Recruiting NCT06317467 - Role of Anti-C1q Autoantibodies in Pregnancy
Completed NCT02218931 - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes N/A
Active, not recruiting NCT04484766 - Preeclampsia Associated Vascular Aging
Completed NCT03509805 - Sleep Apnea Syndrome in Obese Women During Pregnancy N/A